HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alaupovic, P. Articles by Gregg, R. E. Search for Related Content PubMed PubMed Citation Articles by Alaupovic, P. Articles by Gregg, R. E. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 32, 9-19, Copyright © 1991 by Lipid Research, Inc.

ARTICLES

Isolation and characterization of an apoA-II-containing lipoprotein (LP- A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia

P Alaupovic, C Knight-Gibson, CS Wang, D Downs, E Koren, HB Brewer Jr and RE Gregg
Lipoprotein and Atherosclerosis Research Program, Oklahoma Medical Research Foundation, Oklahoma City.

Previous studies have shown that very low density lipoproteins (VLDL) from patients with Tangier disease are less effective as a substrate for human milk lipoprotein lipase (LPL) than VLDL from normal controls as assessed by measuring the first order rate constant (k1) of triglyceride hydrolysis. Tangier VLDL also has a higher content of apolipoprotein (apo) A-II than normal VLDL. To explore the possible relationship between the relatively high concentration of apoA-II in VLDL and low k1 values, Tangier VLDL were fractionated on an anti-apoA- II immunosorber. The retained fraction contained a newly identified triglyceride-rich lipoprotein characterized by the presence of apolipoproteins A-II, B, C-I, C-II, C-III, D, and E (LP-A-II:B:C:D:E or LP-A-II:B complex), whereas the unretained fraction consisted of previously identified triglyceride-rich apoB-containing lipoproteins free of apoA-II. In VLDL from patients with Tangier disease or type V hyperlipoproteinemia, the LP-A-II:B complex accounted for 70-90% and 25- 70% of the total apoB content, respectively. The LP-A-II:B complexes had similar lipid and apolipoprotein composition; they were poor substrates for LPL as indicated by their low k1 values (0.014-0.016 min- 1). In contrast, the apoA-II-free lipoproteins present in unretained fractions were effective substrates for LPL with k1 values equal to or greater than 0.0313 min-1. These results indicate that triglyceride- rich lipoproteins consist of several apoB-containing lipoproteins, including the LP-A-II:B complex, and that lipoprotein particles of similar size and density but distinct apolipoprotein composition also possess distinct metabolic properties.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. W. Castellani, C. N. Nguyen, S. Charugundla, M. M. Weinstein, C. X. Doan, W. S. Blaner, N. Wongsiriroj, and A. J. Lusis Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance J. Biol. Chem., April 25, 2008; 283(17): 11633 - 11644. [Abstract] [Full Text] [PDF]

				S. Dugue-Pujol, X. Rousset, D. Pastier, N. T. Quang, V. Pautre, J. Chambaz, M. Chabert, and A.-D. Kalopissis Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism J. Lipid Res., December 1, 2006; 47(12): 2631 - 2639. [Abstract] [Full Text] [PDF]

				F. Blanco-Vaca, J. C. Escola-Gil, J. M. Martin-Campos, and J. Julve Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein J. Lipid Res., November 1, 2001; 42(11): 1727 - 1739. [Abstract] [Full Text] [PDF]

				J. C. Escolà-Gil, J. Julve, A. Marzal-Casacuberta, J. Ordóñez-Llanos, F. González-Sastre, and F. Blanco-Vaca Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia J. Lipid Res., August 1, 2000; 41(8): 1328 - 1338. [Abstract] [Full Text]

				J. S. Cohn, C. Marcoux, and J. Davignon Detection, Quantification, and Characterization of Potentially Atherogenic Triglyceride-Rich Remnant Lipoproteins Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2474 - 2486. [Abstract] [Full Text] [PDF]

				H. N. Hodis Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis Circulation, June 8, 1999; 99(22): 2852 - 2854. [Full Text] [PDF]

				E. Boisfer, G. Lambert, V. Atger, N. Q. Tran, D. Pastier, C. Benetollo, J.-F. Trottier, I. Beaucamps, M. Antonucci, M. Laplaud, et al. Overexpression of Human Apolipoprotein A-II in Mice Induces Hypertriglyceridemia Due to Defective Very Low Density Lipoprotein Hydrolysis J. Biol. Chem., April 23, 1999; 274(17): 11564 - 11572. [Abstract] [Full Text] [PDF]

				P. Alaupovic, W. J. Mack, C. Knight-Gibson, and H. N. Hodis The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial Arterioscler. Thromb. Vasc. Biol., April 1, 1997; 17(4): 715 - 722. [Abstract] [Full Text]

				A. von Eckardstein, Y. Huang, S. Wu, H. Funke, G. Noseda, and G. Assmann Reverse Cholesterol Transport in Plasma of Patients With Different Forms of Familial HDL Deficiency Arterioscler. Thromb. Vasc. Biol., May 1, 1995; 15(5): 691 - 703. [Abstract] [Full Text]